Skip to main content

USPTO to Issue RXi siRNA Sequence-Specific Patents


RXi Pharmaceuticals this week said it has received notices of allowance from the US Patent and Trademark Office on patent applications, filed by Thermo Fischer Scientific and licensed to RXi, covering siRNA sequences against a number of gene targets.

Specifically, the applications cover siRNAs targeting superoxide dismutase, amyloid beta precursor protein, interleukin-1 receptor-associated kinase 4, hepatocyte growth factor receptor, and cyclin-dependent kinase inhibitor p27, RXi said.

"These sequence-specific patent applications and the ones we expect to follow add another important component to our robust intellectual property portfolio," RXi President and CEO Tod Woolf said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.